Torexvis eye drops 0,3% Gia Nguyen Phong lan nambani inflammation lan nyegah infèksi (5ml)

Bentuk sediaan Botol X 5ml Kab
Spesifikasi Tobramycin, deksametason

Komposisi

Informasi komposisi	Isi
Tobramycin	15 mg
Deksametason	5 mg

Migunakake

indications Tore - d drugs are indicated in the following cases: Small eye fluid containing Tobramycin and Dexamethason are indicated for eye inflammation in the eye response to steroids that are indicated for corticosteroids and when bacterial infections are infected by bacteria or bacterial eye infections. Small steroids are indicated in cases of lashic conjunctivitis and eye conjunctivitis, keratitis and the front of the eyeball when accepting the inherent risks of the use of steroids in conjunctivitis to reduce inflammation and edema. The drug is also prescribed in chronic phenomenon before chronic and chemical corneal damage, radiation or thermal burns or foreign objects. The use of drugs in combination with an antibacterial ingredient is indicated when there is a high risk of shallow infections in the eye or when there is a prediction of the possibility of a large number of bacteria present in. Tobramycin in this product is active against common bacteria that cause eye diseases as follows: Staphylococci, including S. Aureus and S. Epidermidis (positive coagulase and negative coagulase), including penicillin resistance strains. Aerµginosa, Escherichia Coli, Klebsiella Pneumoniae, Enterobacter Aerogenes, Proteus Mirabilis, Morganella Morganii, most of them Proteus Vulgaris, Haemophilus Influenzae and H. Aegptius, Moraxella Lacunata, Acinetobacter CaloactericiCiCiCiCiTiciciic and a few Neisseria species. ATC code: 501ca01. dexamethasone: The effect of corticosteroids in treating eye inflammation has been recognized. Corticosteroids have anti -inflammatory effects through inhibiting the adhesive molecules of blood vascular cells, cyclooxygenase I or II, and the manifestations of cytokin, leading to a reduction in the expression of intermediate inflammatory substances and inhibit the approach of white blood cells to the intravascular, thereby preventing their movement on the inflammatory tissue of the eye. Dexamethason is one of the substances with strong anti -inflammatory activity, and low mineralocorticoid activity compared to other steroids. Tobramycin: Tobramycin is an aminoglycoside antibiotic with strong activity, wide antibacterial spectrum and fast effect. The drug acts on bacterial cells mainly through inhibiting the synthesis and assembly of polypeptide chains on ribosom. Tobramycin in preparations works against sensitive bacteria. Determination of sensitivity is based on the following minimum inhibitory concentration (MIC) used to classify bacterial strains into 3 sensitive levels (s), intermediate (i) and resistance (R): s ≤ 4 µg/mi, r ≥ 8µg/ml. The frequency of drug resistance may vary between regions, the time of sampling and information about local drug resistance, especially when treating severe cases of infections. Must consult a consultant when knowing the percentage of drug resistance in the locality but has not determined the effect of Tobramycin with some infections. The following information only gives relatively instructions on bacterial sensitivity to Tobramycin in preparations. Determination of bacterial sensitivity is very useful in predicting the clinical effect of antibiotics when using the whole body. However, these values may not be applied to local eye drops due to the higher local concentration. Many bacteria that have been classified as anti -drug -based drugs are well treated when used on the spot. In vitro studies show that Tobramycin has the strongest effect against the majority of strains of pathogens in the eye and on the skin as common as listed in the following table: Bacterial strain The frequency of resistance in Europe Aerobic gram -positive bacteria corynebacterium species Staphylococcus aureus (Methicillin sensitivity) Staphylococcus epidermidis (methicillin sensitivity) Staphylococci coagulase negative other 0-3% 0-3% 0-28% 0-40% Drug -resistant bacteria Aerobic gram -positive bacteria Enterococcus Species Staphylococcus aureus resistant to methicillin Staphylococcus epidermidis resistant methicillin streptococcus pneumoniae Streptococcus Species 50-70% 30-40% Acinetobacter Species, Citrobacter Species, Escherichia Coli, Entobacter Species, Haemophilus Influenzae, Klebsiella Species, Moraxella Species, Proteus Species. Pseudomonas aerµginosa 0% Aerobic gram bacteria Burkholeria Cepacia stenotrophomonas maltophilia Gram -negative bacteria understand the air Serratia Marcescens Mandatory anaerobic bacteria Using clinical drugs, but the data is still limited. A clinical study conducted on 29 children aged 1 to 17 years old with conjunctivitis, treated by 1 to 2 drops of small eye suspension every 4 or 6 hours in 5 or 7 days. As a result, there is no observation of the difference in safety data between adults and children. Other information: Cross -resistance between aminoglycosides (eg gentamycin and tobramycin) is due to the specificity of adenyl altered enzymes (adenyltransferase) and acetyl group (acetyltransferase). However, diagonal resistance is very different between aminoglycosides due to the various specific characteristics of changing enzymes. The most common resistance mechanism is antibiotic inhibition by transformed enzymes encrypted on plasmid and transposon. Dynamic pharmacokinetics Tobramycin: Animal studies show that Tobramycin has absorbed through the cornea after the eye -catching time of the drug in people with normal renal function is about 2 hours. Tobramycin is almost excreted through glomerular filtration in unchanged form. Tobramycin concentration in serum after 2 small eyes in most patients is below the quantitative limit (≤ 0.25 mcg/ml). dexamethason: After small eyes, dexamethason absorbs with maximum concentrations into the cornea and aquatic fluid for 1-2 hours of sale time of the drug's exhaust time is about 3 hours. Dexamethason excreted mainly in the form of metabolites. Dexamethasone is less absorbed in the circulation after using the eye on the spot. The peak concentration of dexamnethason in plasma is from 220 to 888 PG/ml (555 ± 217 PG/ml) after using the small eye mixture at a dose of 1 drop per eye, 4 times a day for 2 consecutive days.

Sadurunge njupuk Torexvis eye drops 0,3% Gia Nguyen Phong lan nambani inflammation lan nyegah infèksi (5ml)

Cara nggunakake

Cara nggunakake: Goyangake vial sadurunge digunakake. Kanggo ngindhari infeksi menyang pucuk cilik obat lan kekacauan obat, aja nganti sirah obat kasebut kena ing kelopak mata, area sekitar mata utawa obyek apa wae. Nutup tutup nalika ora digunakake. Ing kasus nggunakake simultaneous karo irungnya mripat ing panggonan liya, kudu njupuk 5 menit loro. Ointments kudu digunakake pungkasan.

Dosis

Wong diwasa: Pasang ing saben mripat 1 tetes saben 4-6 jam. Ing 24 - 48 jam pisanan, dosis bisa ditambah dadi 1 tetes saben 2 jam. Sampeyan kudu nyuda jumlah obat cilik nalika gejala klinis saya apik. Ati-ati ngirim ora mandheg nambani banget awal. Lansia: Pasinaon klinis nuduhake yen ora perlu nyetel dosis nalika njupuk obat ing wong tuwa.

Bocah-bocah: Torexvis-D bisa digunakake ing bocah-bocah luwih saka 2 taun kanthi dosis kaya ing wong diwasa. Keamanan lan efektifitas obat kanggo bocah-bocah ing umur 2 taun durung ditetepake lan ora ana angka tartamtu.

Cathetan: Dosis ing ndhuwur mung kanggo referensi. Dosis spesifik gumantung saka kahanan lan tingkat kemajuan penyakit kasebut. Kanggo dosis sing cocog, sampeyan kudu takon dhokter utawa spesialis medis.

Apa sing kudu ditindakake nalika overdosis? Yen mripat wis overdosis, sampeyan bisa ngumbah mata nganggo banyu anget sing anget kanggo ngilangi.

Yen ana darurat, hubungi puskesmas 115 langsung utawa menyang puskesmas sing paling cedhak.

Apa sing kudu ditindakake yen sampeyan lali 1 dosis? Nanging, yen wektu kanggo ngendhokke karo dosis sabanjuré cendhak banget, skip dosis lan terus tanggalan tamba. Aja nggunakake dosis kaping pindho kanggo ngimbangi dosis sing ora kejawab.

Efek sisih

When using Torexvis - D, you may experience unwanted effects (ADR) such as: The following adverse reactions have been reported in clinical and data tests during the circulation of drugs classified according to the following conventions: Very common (≥ 1/10), common (≥ 1/100 to

Pènget

Sadurunge nggunakake obat sampeyan kudu maca instruksi kasebut kanthi teliti lan deleng informasi ing ngisor iki.

Contraindicated

Torexvis - D contraindicated ing kasus ing ngisor iki:

Hipersensitivitas kanggo Tobramycin utawa Dexamethasone utawa bahan-bahan obat kasebut. Leprae, Mycobacterium avium.

Ati-ati nalika nggunakake

kudu ati-ati banget nalika njupuk obat kanggo pasien ing kasus ing ngisor iki:

Mung nganggo mripat cilik ing panggonan, aja ngombe utawa nyuntikake.

Panganggone kortikosteroid sing tahan suwe (luwih saka 24 dina) bisa nyebabake glaukoma/glaukoma, diiringi karusakan saraf optik, penglihatan lan cacat pasar, lan katarak ing ngisor iki.

Kudu ngawasi tekanan reguler. Iki penting banget ing pasien sing isih bocah amarga risiko glaukoma amarga steroid ing bocah-bocah ing umur 6 taun lan katon luwih awal ing wong diwasa. Frekuensi lan suwene perawatan kudu dipikirake kanthi ati-ati lan kudu ngawasi glaukoma wiwit wiwitan perawatan kanggo ndeteksi glaukoma sing disebabake dening steroid ing bocah-bocah.

Kemampuan kanggo nambah glaukoma lan/utawa katarak luwih dhuwur tinimbang pasien sing duwe risiko (kayata pasien diabetes).

Panggunaan sing dawa bisa nyebabake infeksi sekunder amarga nyuda respon awak. Kortikosteroid bisa nyuda resistensi awak, nyebabake infeksi, infeksi jamur utawa virus lan nutupi tandha-tandha infeksi.

Kanggo sawetara pasien bisa kedadeyan fenomena sensitif kanthi aminoglikosida digunakake ing papan kasebut. Yen reaksi sensitif kedadeyan, mungkasi obat kasebut.

Bisa uga ana resistensi silang karo aminoglikosida liyane.

Efek serius sing ora dikarepake kalebu keracunan saraf, kuping lan ginjel sing bisa kedadeyan ing pasien sing nggunakake aminoglikosida sistemik. Kudu ati-ati yen digunakake bebarengan.

Kudu curiga infèksi jamur ing pasien karo ulkus kornea sing dawa. Yen ana infeksi jamur, kortikosteroid kudu dihentikan.

Kanggo nggunakake antibiotik sing berpanjangan bisa nyebabake tuwuhing galur bakteri sing ora sensitif, kalebu jamur. Yen superinfeksi kedadeyan, perawatan sing cocog kudu diwiwiti. Nggunakake kortikosteroid cilik bisa nyuda tatu. Panganggone steroid lan NSAID tocalide bisa ningkatake risiko ulkus kornea.

Ing penyakit tipis kornea utawa fraktur, ana kasus nalika jembatan wis kedadeyan nalika nggunakake kortikosteroid lokal.

Komponen benzalkonium klorida wis dilaporake nyebabake keratitis lan/utawa ulkus kornea. Benzalkonium klorida uga bisa nyebabake iritasi mata lan ngganti lensa kontak alus. Aja nganti kena lensa kontak alus.

Sajrone perawatan infeksi utawa inflamasi ing mripat, aja nganggo lensa kontak. Yen pasien diidini nganggo lensa kontak, lensa kasebut kudu dicopot sadurunge obat kasebut lan mung nganggo sawise 15 menit.

Efek obat kasebut ing kemampuan kanggo nyopir lan ngoperasikake mesin

Torexvis-D mripat ora signifikan utawa diabaikan kanggo nyopir lan ngoperasikake mesin. Ora ana riset babagan efek obat ing nyopir lan mesin operasi. Kaya irungnya mripat liyane, sesanti burem sementara utawa kelainan sesanti bisa mengaruhi kemampuan kanggo nyopir lan ngontrol mesin. Yen sampeyan katon burem nalika mripate cilik, pasien kudu ngenteni nganti cetha banjur nyopir lan ngontrol mesin kasebut. Sawetara pasien bisa ngalami efek obat sing ora dikarepake kayata sirah, pusing sing mengaruhi kemampuan nyopir lan ngontrol mesin. Yen ngono, pasien ora kudu nyopir utawa ngoperasikake mesin.

Gunakake obat kanggo wanita nalika meteng lan laktasi

Kandhutan

Ora ana riset sing nyukupi lan dikontrol ing wanita ngandhut. Pasinaon kewan karo Tobramycin sing disuntikake subkutan ora dideteksi efek teratogenik. Gunakake aminoglikosida awak doksik dhuwur. Nanging, sawise mripat cilik, jumlah panyerepan obat kurang banget lan Tobramycin ora nyebabake cilaka langsung utawa ora langsung kanggo reproduksi. Nggunakake kortikosteroid topikal kanggo kewan sing ngandhut bisa nyebabake kelainan kanggo perkembangan janin, kalebu langit-langit. Data kewan lan klinis nuduhake yen panggunaan glukokortikoid sajrone meteng bisa nambah risiko retardasi janin ing uterus, penyakit kardiovaskular lan / utawa metabolisme lan / utawa nyuda neurologis. Panganggone obat-obatan nalika meteng, utamane ing 3 wulan pisanan, mung dituduhake sawise ngevaluasi kabutuhan kanggo keuntungan ginjel - risiko. Mulane, sampeyan kudu ngandhani dhokter yen sampeyan lagi ngandhut. Nganti saiki, panggunaan obat-obatan ing manungsa durung nuduhake bukti sing mengaruhi janin. Nanging, panggunaan sing dawa ora ngilangi kemungkinan nyebabake gangguan pertumbuhan ing janin. Perawatan ing pungkasan meteng bisa nyandhet biosintesis biosintesis glukokortikoid awak sawise lair. Mulane, mung nggunakake Torexvis-D lam mripat kanggo wanita ngandhut yen keuntungan kanggo ibu resiko pinunjul kanggo jabang bayi

Periode nyusoni

kortikosteroid katon ing ASI sawise nggunakake gula sistemik lan bisa nyandhet wutah, ngganggu biosintesis kortikosteroid endogen utawa nyebabake efek negatif liyane. Ora dingerteni manawa nggunakake kortikosteroid topikal bisa nyebabake penyerapan lan ekskresi menyang susu ibu kanthi jumlah deteksi utawa ora. Torexvis-D ora kena digunakake sajrone nyusoni kajaba keuntungan kasebut ora ana risiko.

Interaksi obat

ora ana interaksi khusus sing dilaporake kanggo tetes mata. Panganggone steroid lan NSAID tocalide bisa nambah risiko ulkus kornea.

Panyimpenan

Ninggalake papan sing adhem, aja nganti cahya, suhu ngisor 30⁰C.

Supaya ora bisa digayuh bocah-bocah, waca instruksi kasebut kanthi teliti sadurunge digunakake.

Obat liyane

Disclaimer

Kabeh upaya wis ditindakake kanggo mesthekake yen informasi sing diwenehake dening Drugslib.com akurat, nganti -tanggal, lan lengkap, nanging ora njamin kanggo efek sing. Informasi obat sing ana ing kene bisa uga sensitif wektu. Informasi Drugslib.com wis diklumpukake kanggo digunakake dening praktisi kesehatan lan konsumen ing Amerika Serikat lan mulane Drugslib.com ora njamin sing nggunakake njaba Amerika Serikat cocok, kajaba khusus dituduhake digunakake. Informasi obat Drugslib.com ora nyetujoni obat, diagnosa pasien utawa menehi rekomendasi terapi. Informasi obat Drugslib.com minangka sumber informasi sing dirancang kanggo mbantu praktisi kesehatan sing dilisensi kanggo ngrawat pasien lan / utawa nglayani konsumen sing ndeleng layanan iki minangka tambahan, lan dudu pengganti, keahlian, katrampilan, kawruh lan pertimbangan babagan perawatan kesehatan. praktisi.

Ora ana bebaya kanggo kombinasi obat utawa obat sing diwenehake kanthi cara apa wae kudu ditafsirake kanggo nuduhake yen obat utawa kombinasi obat kasebut aman, efektif utawa cocok kanggo pasien tartamtu. Drugslib.com ora nanggung tanggung jawab kanggo aspek kesehatan apa wae sing ditindakake kanthi bantuan informasi sing diwenehake Drugslib.com. Informasi sing ana ing kene ora dimaksudake kanggo nyakup kabeh panggunaan, pituduh, pancegahan, bebaya, interaksi obat, reaksi alergi, utawa efek samping. Yen sampeyan duwe pitakon babagan obat sing sampeyan gunakake, takon dhokter, perawat utawa apoteker.